Immune-Related Adverse Events in Cancer Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 2176
Special Issue Editors
Interests: medical oncology; immune checkpoint inhibitor toxicities; immunotherapy
Special Issue Information
Dear Colleagues,
Over the last decade, immunotherapy treatments, particularly immune checkpoint inhibitors, have brought about a paradigm shift in the treatment of multiple solid tumors. These drugs are now used in many settings, from neoadjuvant through to advanced disease, across a wide variety of tumor types and in combination with other systemic anti-cancer therapies, including chemotherapy and tyrosine kinase inhibitors. While these checkpoint inhibitor drugs have revolutionized outcomes for some patients, understanding and treating their attendant side effects, or immune-related adverse events (irAEs), have provided new challenges for the oncology community. While we now know more about the spectrum of irAEs expected with ICIs, less is known about their long-term impact, how best to predict who may suffer from irAEs, how best to capture data on irAEs in clinical trials and in the real world, the mechanisms underlying the different irAEs, how best to treat them, particularly in steroid refractory cases or rarer irAEs, and how to educate our patients and the wider medical community about these very different side effects. Less is still known about the adverse events associated with some of the newer immunotherapies or combination treatments.
This Special Issue ‘Immune-Related Adverse Events in Cancer Immunotherapy’ aims to focus on these topics and more. In this Special Issue, original research articles and reviews are welcome.
We look forward to receiving your contributions.
Dr. Kate Young
Dr. Anna Olsson-Brown
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- check point inhibitors (CPIs)
- immunotherapy
- irAEs
- immune checkpoint inhibitors (ICIs)
- survivorship
- long-term toxicity
- steroid refractory
- biologics
- CAR-T
- TILs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
